$316.93 Million in Sales Expected for Horizon Pharma PLC (HZNP) This Quarter
Wall Street analysts predict that Horizon Pharma PLC (NASDAQ:HZNP) will report sales of $316.93 million for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Horizon Pharma’s earnings, with estimates ranging from $313.77 million to $320.23 million. Horizon Pharma reported sales of $271.65 million during the same quarter last year, which indicates a positive year-over-year growth rate of 16.7%. The company is scheduled to issue its next earnings report on Monday, November 5th.
According to Zacks, analysts expect that Horizon Pharma will report full year sales of $1.18 billion for the current fiscal year, with estimates ranging from $1.17 billion to $1.19 billion. For the next financial year, analysts expect that the company will post sales of $1.28 billion per share, with estimates ranging from $1.23 billion to $1.34 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 EPS for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.17. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. The company had revenue of $302.84 million for the quarter, compared to analysts’ expectations of $275.51 million. During the same period in the previous year, the firm earned $0.41 EPS. The firm’s revenue was up 4.6% compared to the same quarter last year.
NASDAQ HZNP opened at $20.57 on Friday. The company has a debt-to-equity ratio of 2.19, a quick ratio of 1.63 and a current ratio of 1.70. Horizon Pharma has a 12 month low of $11.17 and a 12 month high of $21.25. The company has a market capitalization of $3.49 billion, a P/E ratio of 17.34, a price-to-earnings-growth ratio of 1.26 and a beta of 1.43.
In other Horizon Pharma news, Chairman Timothy P. Walbert sold 83,353 shares of Horizon Pharma stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $16.17, for a total value of $1,347,818.01. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Brian K. Beeler sold 15,433 shares of the business’s stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $17.58, for a total value of $271,312.14. The disclosure for this sale can be found here. In the last ninety days, insiders sold 116,717 shares of company stock worth $1,907,999. Corporate insiders own 3.90% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HZNP. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 3,877 shares during the last quarter. D.A. Davidson & CO. bought a new position in shares of Horizon Pharma during the 1st quarter valued at approximately $143,000. Zweig DiMenna Associates LLC bought a new position in shares of Horizon Pharma during the 1st quarter valued at approximately $156,000. Quantitative Systematic Strategies LLC bought a new position in shares of Horizon Pharma during the 2nd quarter valued at approximately $172,000. Finally, Strs Ohio increased its position in shares of Horizon Pharma by 74.2% during the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 4,600 shares during the last quarter. 84.62% of the stock is currently owned by hedge funds and other institutional investors.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Featured Story: Find a Trading Strategy That Works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.